Why the study?
Does intravenous 7E3-F(ab')2 inhibit platelet aggregation in a human neomort model?
Does intravenous 7E3-F(ab')2 inhibit platelet aggregation in a human neomort model?
The 7E3-F(ab')2 monoclonal antibody fragment demonstrates potent, immediate-acting inhibition of platelet aggregation in a human neomort model, providing early evidence for its potential as an antithrombotic agent.
No takes yet. Share an insight, caveat, or question.
Supports further study of 7E3-F(ab')2 for antithrombotic use; leaves open efficacy and safety in living patients.
Barry S. Coller (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: